LadRx Corporation(LADX.US)

Company Encyclopedia
View More
name
LadRx Corporation
LADX.US
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent that targets and delivers the chemotoxic agent to the tumor environment and release within the tumor. Its lead candidates comprising LADRs 7, 8, 9, and 10 with novel derivatives of the auristatin and maytansinoid drug targeting tumors; and aldoxorubicin, which is in phase II clinical development for the treatment of pancreatic cancer. In addition, the company develops albumin companion diagnostic (ACDx) to identify patients with cancer that benefits from treatment with the four LADR lead candidates.
1.897 T
LADX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    LadRx Corporation Announces Intent to Seek FDA Marketing Approval for Aldoxorubicin Despite Resource Limitations

    LadRx Corporation announced its intent to seek FDA marketing approval for aldoxorubicin on December 11, 2024. The company plans to use existing clinical and supplemental non-clinical data under section 505(b)(2). However, it has determined that it currently lacks the necessary resources to proceed with the approval process. No information on potential funding or grants has been disclosed.

    Reuters·
    US
    LADX
    0.00%
    Reuters·
    US
    LADX
    0.00%

    LadRx Corporation | 10-Q: FY2025 Q1 EPS: USD -1.45

    LB filings·
    US
    LADX
    0.00%
    LB filings·
    US
    LADX
    0.00%

    LadRx Corporation, Inc. to Present at the Virtual Life Science Investor Forum March 13th

    LadRx Corporation (OTCQB: LADX) will present at the Virtual Life Science Investor Forum on March 13, 2025, at 3:00 PM ET. CEO Stephen Snowdy, PhD, will lead the presentation, allowing real-time investor questions. The company is advancing aldoxorubicin, a novel cancer therapeutic, towards FDA approval under Section 505(b)(2), expecting to complete necessary studies within 6-8 months of funding. Aldoxorubicin aims to enhance doxorubicin delivery to tumors while minimizing side effects. Investors can pre-register for the event and access an archived webcast afterward.

    Benzinga·
    US
    LADX
    0.00%
    Benzinga·
    US
    LADX
    0.00%
    © 2026 Longbridge｜Disclaimer